{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4479","upperLimit":"53,879","value":"29,179"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Measurement of NY-ESO-1ᶜ²⁵⁹T cells in blood (copies of WPRE per µg of genomic PBMC DNA)","dispersionType":"Full Range","groups":[{"description":"Participants who received cytoreductive chemotherapy followed by infusion of lentivirus-mediated genetically engineered NY-ESO-1ᶜ²⁵⁹T (Target dose: 1-10 billion cells)","id":"OG000","title":"NY-ESO-1ᶜ²⁵⁹T Cells Administered IV"}],"paramType":"MEAN","populationDescription":"Participants who received cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T with persistence data","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 15, 22, 29, 43, 101, 130 181, every 3 months thereafter","title":"Peak Persistence of Modified T-cells in the Peripheral Blood","type":"SECONDARY","unitOfMeasure":"copies per μg of DNA"}